Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 May 19:7:241.
doi: 10.3389/fmed.2020.00241. eCollection 2020.

Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir

Tatsuhiko Wada  1 , Kosuke Shimode  1 , Takayuki Hoshiyama  1   2 , Yoko Takayama  2 , Kunihiro Yamaoka  1
Affiliations
Case Reports

Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir

Tatsuhiko Wada et al. Front Med (Lausanne). .

Abstract

Following the first case of Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-Cov-2), in Wuhan, China, in December 2019, it has spread worldwide. An outbreak in Japan occurred on a cruise ship, and this was followed by community-acquired COVID-19. Herein, we report three cases of COVID-19 that presented pneumonia following admission to Kitasato University Hospital. Patients were admitted based on the positive result of real-time reverse transcriptase-polymerase chain reaction (RT-PCR) tests for COVID-19 nucleic acid. All patients were diagnosed as suffering from non-severe COVID-19 pneumonia and were successfully treated with Lopinavir/Ritonavir (LPV/r). LPV/r could be an option for treating non-severe COVID-19 pneumonia in general and even in elderly patients.

Keywords: COVID-19; Lopinavir; Ritonavir; cruise ship; elderly patient; hyponatremia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Clinical course of patient 1.
Figure 2
Figure 2
Clinical course of patient 2.
Figure 3
Figure 3
Clinical course of patient 3. BT, body temperature; CT, computed tomographic scan; CXP, chest X-ray photograph; Neg, negative PCR test; PCR, polymerase chain reaction test for COVID-19 nucleic acid; Pos, positive PCR test; RV, reference value.
Figure 4
Figure 4
Initial computed tomographic images of patients 1 (P1), 2 (P2), and 3 (P3) with COVID-19 pneumonia (A) and those after treatment with Lopinavir/Ritonavir (B).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497–506. 10.1016/S0140-6736(20)30183-5 - DOI - PMC - PubMed
    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. (2020) 323:1239–42. 10.1001/jama.2020.2648 - DOI - PubMed
    1. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care. (2020) 24:108. 10.1186/s13054-020-2833-7 - DOI - PMC - PubMed
    1. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. (2020) 25:2000180. 10.2807/1560-7917.ES.2020.25.10.2000180 - DOI - PMC - PubMed
    1. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. . Role of Lopinavir/Ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. (2004) 59:252–6. 10.1136/thorax.2003.012658 - DOI - PMC - PubMed

Publication types